Infliximab-induced autoimmune hepatitis. Issue 5 (24th May 2021)

• Record Type: Journal Article
• Authors: Jenkins, Alexander; Austin, Amy; Hughes, Kathryn; Sadowski, Brett; Torres, Dawn
• Is Part Of: BMJ case reports. Volume 14:Issue 5(2021)
• Publication Date: 2021-05-24
• Subjects: drugs: gastrointestinal system -- ulcerative colitis -- hepatitis other; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2020-239944
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Autoimmune hepatitis (AIH) is an inflammatory disorder of the liver with a wide spectrum of disease presentation, from asymptomatic elevations in liver-associated enzymes to acute liver failure. AIH is classically associated with elevated immunoglobulins and autoantibodies, although approximately 20% of patients with features of AIH lack circulating antibodies. Recently, tumour necrosis factor alpha inhibitors have been implicated in several cases of drug-induced AIH which impact treatment regimens for patients with inflammatory bowel disease (IBD). We present a case of infliximab-induced seronegative AIH responding to budesonide therapy with successful alteration of IBD treatment regimen to vedolizumab.